KYTX Stock Summary and Trading Ideas (Kyverna Therapeutics | NASDAQ:KYTX)

Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.

Kyverna Therapeutics trades on the NASDAQ stock market under the symbol KYTX.

As of August 14, 2026, KYTX stock price climbed to $8.17 with 554,985 million shares trading.

KYTX has a beta of 1.48, meaning it tends to be more sensitive to market movements. KYTX has a correlation of 0.06 to the broad based SPY ETF.

KYTX has a market cap of $505.26 million. This is considered a Small Cap stock.

The top ETF exchange traded funds that KYTX belongs to (by Net Assets): VTI, IWM, VXF, FESM, IWN.

KYTX has outperformed the market in the last year with a price return of +130.8% while the SPY ETF gained +21.5%. However, in the short term, KYTX had mixed performance relative to the market. It has underperformed in the last 3 months, returning -23.9% vs +4.0% return in SPY. But in the last 2 weeks, KYTX shares have fared better than the market returning +11.9% compared to SPY +3.9%.

KYTX support price is $7.76 and resistance is $8.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYTX shares will trade within this expected range on the day.